Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Fagron NV: Higher turnover and profit for Fagron

Fagron NV
Posted on: 04 Aug 17

Regulated information | Consolidated results for the first half of 2017
Nazareth (Belgium) / Rotterdam (The Netherlands), 4 August 2017

Higher turnover and profit for Fagron
Significant decrease of net debt/REBITDA-ratio


Highlights:
Financial

  • Turnover increases 5.5% to € 221.7 million
  • REBITDA increases 5.6% to € 48.1 million or 21.7% of turnover
  • EBIT increases 13.5% to € 38.4 million or 17.3% of turnover
  • Net profit increases 27.0% to € 21.1 million
  • Strong operating cash flow of € 49.5 million
  • Net financial debt/REBITDA ratio decreases from 3.18 to 2.66

Strategic - operational

  • Sterile compounding facility in Wichita (US) licensed in 46 states (incl. New York, Florida and Texas)
  • Opening of new sterile compounding facility in Hoogeveen (the Netherlands)
  • Sale of non-sterile compounding facility in Paris (France)
  • Acquisition of Kemig, market leader in the sale of pharmaceutical raw materials in Croatia, after the close of H1 2017

Hans Stols, CEO of Fagron : "Fagron can look back on a strong first half of 2017. Our core businesses in Europe, South America and North America achieved good growth in both turnover and profit. The sterile compounding operations in the United States achieved turnover growth of more than 22%, a clear acceleration compared to previous half-years. The costs of the company were well controlled resulting in a profitability that increased faster than turnover.

We also made important operational progress in the past six months. We launched many innovative products and concepts on the market to meet the growing demand for individualised patient care. In South America and in Europe, this included the introduction of TrichoConcept® (a patented total solution for alopecia), Pigmerise® MD (a treatment for vitiligo) and FagronLab® (advanced equipment for pharmaceutical compounding), while in the United States we brought our Lets Gel Kit® (an anaesthetic gel) to the market. We are also pleased with the opening of a new compounding facility in Hoogeveen (the Netherlands) during the first half of 2017. This new facility is an important element of the strategy of strengthening our position in hospitals. In addition, we completed the acquisition of Kemig, a leading supplier of pharmaceutical raw materials and packaging materials to pharmacies and wholesalers in Croatia and Bosnia and Herzegovina, early August 2017.

After refinancing the company last year, we focused on further decreasing our leverage in the first half, as a result of which we are operating comfortably within the covenants for our loans, and have created a solid financial position. We subsequently repaid our bond loan of € 225 million just after the close of the first half-year."


Please open the link below for the press release

Higher turnover and profit for Fagron

Please open the link below for the interim financial statements:

Interim financial statements first semester 2017


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Fagron NV via GlobeNewswire
HUG#2125548
GlobeNewswire
globenewswire.com

Last updated on: 05/08/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.